SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech success, 2002
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (92)9/20/2002 1:18:59 PM
From: keokalani'nui  Read Replies (1) of 117
 
You know, I'm not sure I would peg my reward for a really super drug so greatly on US returns (50/50 profits US; 20/80 Intn'l). There are unique regulatory and other medical/marketing risks in each country, with those in the US being the greatest. I'm thinking ahead to indiplone and would hope the revenue stream is better diversified both geographically and with some portion based on % of sales.

Edit: Of course, I wouldn't be looking for big pharma to take big % of nbix stock either.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News